CD19 and mantle cell lymphoma: A preclinical study using MCL cell lines and mice xenograft model showed that combining ibrutinib with CD19 CAR T cell provided long-term remission of 80–100%, compared to 0–20% for the CAR T cell therapy-only treatment group [185].